Journal article
The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis
Abstract
The Food and Drug Administration approval of ruxolitinib for treatment of myelofibrosis and polycythemia vera has changed the management of patients with myeloproliferative neoplasms. Yet the impact of this therapy on risk of thrombosis, a major cause of morbidity and mortality among these patients, remains unknown. The aim of this study was to evaluate the impact of ruxolitinib on the risk of thrombosis among patients with polycythemia vera or …
Authors
Samuelson BT; Vesely SK; Chai-Adisaksopha C; Scott BL; Crowther M; Garcia D
Journal
Blood Coagulation & Fibrinolysis, Vol. 27, No. 6, pp. 648–652
Publisher
Wolters Kluwer
Publication Date
September 2016
DOI
10.1097/mbc.0000000000000446
ISSN
0957-5235